Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cardiotrophin-1 - Digna Biotech/Biotecnol

Next Previous
X
Search
Drug Profile

Cardiotrophin-1 - Digna Biotech/Biotecnol

Alternative Names: CT-1; Recombinant cardiotrophin-1; Recombinant CT-1

Latest Information Update: 02 Oct 2021

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Biotecnol SA; Digna Biotech; Genentech
  • Developer Biotecnol SA; Digna Biotech
  • Class Cytokines; Interleukins; Recombinant proteins
  • Mechanism of Action Apoptosis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ischaemia; Reperfusion injury; Liver failure
  • New Molecular Entity Yes
  • Available For Licensing Yes - Diabetes mellitus; Liver failure

Highest Development Phases

  • Phase II Reperfusion injury
  • No development reported Acute kidney injury; Diabetes mellitus; Ischaemia; Liver failure; Obesity

Most Recent Events

  • 28 Jan 2019 No recent reports of development identified for phase-I development in Acute kidney injury(Prevention) in Spain (IV)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Ischaemia(Prevention) in Spain (IV)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Liver-failure in Spain (IV, Infusion)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top